Cargando…
Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease
BACKGROUND: The discovery that heterozygous missense mutations in the gene encoding triggering receptor expressed on myeloid cells 2 (TREM2) are risk factors for Alzheimer’s disease (AD), with only the apolipoprotein E (APOE) ε4 gene allele conferring a higher risk, has led to increased interest in...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709982/ https://www.ncbi.nlm.nih.gov/pubmed/26754172 http://dx.doi.org/10.1186/s13024-016-0071-x |
_version_ | 1782409753562972160 |
---|---|
author | Heslegrave, Amanda Heywood, Wendy Paterson, Ross Magdalinou, Nadia Svensson, Johan Johansson, Per Öhrfelt, Annika Blennow, Kaj Hardy, John Schott, Jonathan Mills, Kevin Zetterberg, Henrik |
author_facet | Heslegrave, Amanda Heywood, Wendy Paterson, Ross Magdalinou, Nadia Svensson, Johan Johansson, Per Öhrfelt, Annika Blennow, Kaj Hardy, John Schott, Jonathan Mills, Kevin Zetterberg, Henrik |
author_sort | Heslegrave, Amanda |
collection | PubMed |
description | BACKGROUND: The discovery that heterozygous missense mutations in the gene encoding triggering receptor expressed on myeloid cells 2 (TREM2) are risk factors for Alzheimer’s disease (AD), with only the apolipoprotein E (APOE) ε4 gene allele conferring a higher risk, has led to increased interest in immune biology in the brain. TREM2 is expressed on microglia, the resident immune cells of the brain and has been linked to phagocytotic clearance of amyloid β (Aβ) plaques. Soluble TREM2 (sTREM2) has previously been measured in cerebrospinal fluid (CSF) by ELISA but in our hands commercial kits have proved unreliable, suggesting that other methods may be required. We developed a mass spectrometry method using selected reaction monitoring for the presence of a TREM2 peptide, which can be used to quantify levels of sTREM2 in CSF. FINDINGS: We examined CSF samples from memory clinics in Sweden and the UK. For all samples the following were available: clinical diagnosis, age, sex, and measurements of the CSF AD biomarkers Aβ42, T-tau and P-tau(181). AD patients (n = 37) all met biomarker (IWG2) criteria for AD. Control individuals (n = 22) were cognitively normal without evidence for AD in CSF. We found significantly higher sTREM2 concentration in AD compared to control CSF. There were significant correlations between CSF sTREM2 and T-tau as well as P-tau(181). CSF sTREM2 increase in AD was replicated in a second, independent cohort consisting of 24 AD patients and 16 healthy volunteers. CONCLUSION: CSF concentrations of sTREM2 are higher in AD than in controls, and correlate with markers of neurodegeneration. CSF sTREM2 may be used to quantify glial activation in AD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13024-016-0071-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4709982 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47099822016-01-13 Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease Heslegrave, Amanda Heywood, Wendy Paterson, Ross Magdalinou, Nadia Svensson, Johan Johansson, Per Öhrfelt, Annika Blennow, Kaj Hardy, John Schott, Jonathan Mills, Kevin Zetterberg, Henrik Mol Neurodegener Short Report BACKGROUND: The discovery that heterozygous missense mutations in the gene encoding triggering receptor expressed on myeloid cells 2 (TREM2) are risk factors for Alzheimer’s disease (AD), with only the apolipoprotein E (APOE) ε4 gene allele conferring a higher risk, has led to increased interest in immune biology in the brain. TREM2 is expressed on microglia, the resident immune cells of the brain and has been linked to phagocytotic clearance of amyloid β (Aβ) plaques. Soluble TREM2 (sTREM2) has previously been measured in cerebrospinal fluid (CSF) by ELISA but in our hands commercial kits have proved unreliable, suggesting that other methods may be required. We developed a mass spectrometry method using selected reaction monitoring for the presence of a TREM2 peptide, which can be used to quantify levels of sTREM2 in CSF. FINDINGS: We examined CSF samples from memory clinics in Sweden and the UK. For all samples the following were available: clinical diagnosis, age, sex, and measurements of the CSF AD biomarkers Aβ42, T-tau and P-tau(181). AD patients (n = 37) all met biomarker (IWG2) criteria for AD. Control individuals (n = 22) were cognitively normal without evidence for AD in CSF. We found significantly higher sTREM2 concentration in AD compared to control CSF. There were significant correlations between CSF sTREM2 and T-tau as well as P-tau(181). CSF sTREM2 increase in AD was replicated in a second, independent cohort consisting of 24 AD patients and 16 healthy volunteers. CONCLUSION: CSF concentrations of sTREM2 are higher in AD than in controls, and correlate with markers of neurodegeneration. CSF sTREM2 may be used to quantify glial activation in AD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13024-016-0071-x) contains supplementary material, which is available to authorized users. BioMed Central 2016-01-12 /pmc/articles/PMC4709982/ /pubmed/26754172 http://dx.doi.org/10.1186/s13024-016-0071-x Text en © Heslegrave et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Short Report Heslegrave, Amanda Heywood, Wendy Paterson, Ross Magdalinou, Nadia Svensson, Johan Johansson, Per Öhrfelt, Annika Blennow, Kaj Hardy, John Schott, Jonathan Mills, Kevin Zetterberg, Henrik Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease |
title | Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease |
title_full | Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease |
title_fullStr | Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease |
title_full_unstemmed | Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease |
title_short | Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease |
title_sort | increased cerebrospinal fluid soluble trem2 concentration in alzheimer’s disease |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709982/ https://www.ncbi.nlm.nih.gov/pubmed/26754172 http://dx.doi.org/10.1186/s13024-016-0071-x |
work_keys_str_mv | AT heslegraveamanda increasedcerebrospinalfluidsolubletrem2concentrationinalzheimersdisease AT heywoodwendy increasedcerebrospinalfluidsolubletrem2concentrationinalzheimersdisease AT patersonross increasedcerebrospinalfluidsolubletrem2concentrationinalzheimersdisease AT magdalinounadia increasedcerebrospinalfluidsolubletrem2concentrationinalzheimersdisease AT svenssonjohan increasedcerebrospinalfluidsolubletrem2concentrationinalzheimersdisease AT johanssonper increasedcerebrospinalfluidsolubletrem2concentrationinalzheimersdisease AT ohrfeltannika increasedcerebrospinalfluidsolubletrem2concentrationinalzheimersdisease AT blennowkaj increasedcerebrospinalfluidsolubletrem2concentrationinalzheimersdisease AT hardyjohn increasedcerebrospinalfluidsolubletrem2concentrationinalzheimersdisease AT schottjonathan increasedcerebrospinalfluidsolubletrem2concentrationinalzheimersdisease AT millskevin increasedcerebrospinalfluidsolubletrem2concentrationinalzheimersdisease AT zetterberghenrik increasedcerebrospinalfluidsolubletrem2concentrationinalzheimersdisease |